Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Microarrays and molecular markers for tumor classification.

Brian Z Ring1, Douglas T Ross

  • 1Applied Genomics Inc, 525 Del Rey Ave #B, Sunnyvale, CA 94085, USA.

Genome Biology
|June 7, 2002
PubMed
Summary

Cancer classification is evolving beyond traditional methods. Gene expression profiling reveals new tumor subclasses that may predict patient outcomes and guide targeted therapy development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune infiltrate populations within distinct tumor immune microenvironments predictive of immune checkpoint treatment outcome.

Scientific reports·2025
Same author

The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort.

Cancer immunology, immunotherapy : CII·2023
Same author

27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study.

Clinical lung cancer·2022
Same author

Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients.

Journal of translational medicine·2022
Same author

Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer.

BMC cancer·2022

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Traditional cancer classification relies on tissue origin and histology.
  • Clinical outcomes and therapeutic responses vary significantly across tumor classes.
  • Emerging molecular markers offer new insights into tumor heterogeneity.

Purpose of the Study:

  • To explore the utility of gene expression profiling in cancer classification.
  • To identify novel molecularly defined tumor subclasses.
  • To assess the potential of these subclasses in predicting clinical behavior and guiding therapeutic strategies.

Main Methods:

  • Analysis of gene expression data from a large cohort of human cancer specimens.
  • Utilizing high-throughput gene measurement techniques.
  • Correlating molecular subclasses with clinical data, including prognosis and treatment response.

Main Results:

  • Discovery of novel tumor subclasses based on comprehensive gene expression patterns.
  • Identification of subclasses that correlate with distinct clinical behaviors and patient prognoses.
  • Some molecular subclasses indicate potential for targeted therapeutic development.

Conclusions:

  • Gene expression profiling provides a powerful tool for refining cancer classification.
  • Molecularly defined subclasses offer opportunities for personalized medicine and novel drug development.
  • Further research is needed to reconcile discrepancies between different molecular studies.

Related Experiment Videos